Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Castration-resistant Prostate Cancer
Open-data reference.
11 US clinical trials · 6 currently recruiting
Active & Recent Trials
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic
NCT06378866
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Duke University
NCT06141993
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Edwin Posadas, MD
NCT05534646
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Deciphera Pharmaceuticals
NCT06966024
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Rana McKay, MD
NCT05502315
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
Virginia Commonwealth University
NCT06636123
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
NCT04090528
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Progenics Pharmaceuticals
NCT03939689
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
NCT02207504
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
NCT03672396
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 4 |
| Phase 2 | 5 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Castration-resistant Prostate Cancer Trial Landscape
ClinicalTrials.gov lists 11 US studies indexed under Castration-resistant Prostate Cancer, and 6 of those are currently open to recruitment — roughly 55% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Castration-resistant Prostate Cancer shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 9 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Castration-resistant Prostate Cancer is led by Progenics Pharmaceuticals with 1 indexed trial, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 11 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Castration-resistant Prostate Cancer?
PlainTrial tracks 11 US clinical trials for Castration-resistant Prostate Cancer, of which 6 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Castration-resistant Prostate Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.